Cinitapride-induced exanthema.
González Gutiérrez
M L
ML
Department of Allergology, Hospital Clinico San Carlos, Madrid, Spain. mgg03m@saludalia.com
Rubio Pérez
M
M
Vázquez Cortés
S
S
Martínez González de Lema
B
B
D000284:Administration, Oral; D000368:Aged; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D004294:Domperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D007114:Immunization; D008297:Male; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D028761:Withholding Treatment
D001549:Benzamides; D018492:Dopamine Antagonists; D017366:Serotonin Receptor Agonists; D004294:Domperidone; C045316:cinitapride; D004298:Dopamine